Actively Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Led by Pfizer · Updated on 2026-04-20
224
Participants Needed
49
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.
CONDITIONS
Official Title
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older at screening
- Locally advanced or metastatic renal cell carcinoma confirmed by histology or cytology
- At least one measurable and untreated lesion
- Adequate blood, liver, heart, and kidney function
- No prior systemic therapy for renal cell carcinoma (immunotherapy after surgery allowed if over 12 months ago)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories
You will not qualify if you...
- Known active brain lesions including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of bleeding or fistula
- History of another cancer within the past 3 years
- History of allogeneic organ or hematopoietic stem cell transplantation
- Active autoimmune diseases needing systemic treatment within past 2 years
- Uncontrolled cardiac or other significant health problems within 6 months before first dose
- Major surgery or severe trauma within 4 weeks before first dose or planned major surgery during study
- History of severe bleeding or clotting problems
- History of esophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, obstruction, or abscess
- Acute, chronic, or symptomatic infections
- History of immunodeficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 49 locations
1
Highlands Oncology Group
Fayetteville, Arkansas, United States, 72703
Actively Recruiting
2
Highlands Oncology Group
Rogers, Arkansas, United States, 72758
Actively Recruiting
3
Highlands Oncology Group
Springdale, Arkansas, United States, 72762
Actively Recruiting
4
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, United States, 91010
Actively Recruiting
5
City of Hope Investigational Drug Services (IDS)
Duarte, California, United States, 91010
Actively Recruiting
6
City of Hope Investigational Drug Services (IDS)
Irvine, California, United States, 92618
Actively Recruiting
7
City of Hope
Irvine, California, United States, 92618
Actively Recruiting
8
City of Hope
Long Beach, California, United States, 90813
Actively Recruiting
9
City of Hope UPLAND
Upland, California, United States, 91786
Actively Recruiting
10
Rocky Mountain Cancer Centers, LLP
Denver, Colorado, United States, 80218
Actively Recruiting
11
City Of Hope - Chicago
Zion, Illinois, United States, 60099
Actively Recruiting
12
Minnesota Oncology Hematology, P.A.
Burnsville, Minnesota, United States, 55337
Actively Recruiting
13
Minnesota Oncology Hematology, P.A.
Chaska, Minnesota, United States, 55318
Actively Recruiting
14
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota, United States, 55433
Actively Recruiting
15
Minnesota Oncology Hematology, P.A.
Edina, Minnesota, United States, 55435
Actively Recruiting
16
Minnesota Oncology Hematology, P.A.
Maple Grove, Minnesota, United States, 55369
Actively Recruiting
17
Minnesota Oncology Hematology, P.A.
Maplewood, Minnesota, United States, 55109
Actively Recruiting
18
Minnesota Oncology Hematology, P.A.
Woodbury, Minnesota, United States, 55125
Actively Recruiting
19
New York Oncology Hematology, P.C.
Albany, New York, United States, 12206
Not Yet Recruiting
20
New York Oncology Hematology - Clifton Park Cancer Center
Clifton Park, New York, United States, 12065
Not Yet Recruiting
21
Grand Strand Medical Center
Myrtle Beach, South Carolina, United States, 295724607
Actively Recruiting
22
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina, United States, 29572
Actively Recruiting
23
Parkway Surgery Center
Myrtle Beach, South Carolina, United States, 29572
Actively Recruiting
24
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
25
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
26
Texas Oncology - Central South
Austin, Texas, United States, 78731
Actively Recruiting
27
Texas Oncology - Central South
Austin, Texas, United States, 78758
Actively Recruiting
28
Texas Oncology - Gulf Coast
Beaumont, Texas, United States, 77702
Actively Recruiting
29
Texas Oncology - Gulf Coast
Houston, Texas, United States, 77024
Actively Recruiting
30
Texas Oncology - Gulf Coast
Houston, Texas, United States, 77054
Actively Recruiting
31
US Oncology Investigational Products Center (IPC)
Irving, Texas, United States, 75063
Actively Recruiting
32
US Oncology Investigational Products Center
Irving, Texas, United States, 75063
Actively Recruiting
33
Texas Oncology - Central South
McAllen, Texas, United States, 78503
Actively Recruiting
34
Texas Oncology - Gulf Coast
Pearland, Texas, United States, 77584
Actively Recruiting
35
Texas Oncology - Gulf Coast
Sugar Land, Texas, United States, 77479
Actively Recruiting
36
Texas Oncology - Gulf Coast
The Woodlands, Texas, United States, 77380
Actively Recruiting
37
Texas Oncology - Gulf Coast
Webster, Texas, United States, 77598
Actively Recruiting
38
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Blacksburg, Virginia, United States, 24060
Actively Recruiting
39
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
Actively Recruiting
40
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Low Moor, Virginia, United States, 24457
Actively Recruiting
41
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Roanoke, Virginia, United States, 24014
Actively Recruiting
42
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Salem, Virginia, United States, 24153
Actively Recruiting
43
Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Wytheville, Virginia, United States, 24382
Actively Recruiting
44
Minnesota Oncology Hematology, P.A.
Hudson, Wisconsin, United States, 54016
Actively Recruiting
45
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia, 4066
Actively Recruiting
46
The University of Osaka Hospital
Suita, Osaka, Japan, 565-0871
Not Yet Recruiting
47
Keio university hospital
Shinjuku-ku, Tokyo, Japan, 1608582
Actively Recruiting
48
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan, 811-1395
Actively Recruiting
49
Yamagata University Hospital
Yamagata, Japan, 990-9585
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here